Neutralizing antibodies are widely viewed as the frontline of antiviral defence. Yet emerging evidence reveals that T cells can terminate infection before it is detectable by routine clinical assays, independently of antibodies. Recognizing this capacity reframes correlates of protection and calls for vaccines that harness T cells as early, decisive defenders.
- Leo Swadling
- Valeria Fumagalli
- Matteo Iannacone